IDEXX Laboratories (IDXX) Akcie Kurz
IDEXX Laboratories Kurz
Za posledních 19 let vzrostly tržby IDEXX Laboratories o 9,7 % ročně a dosáhly 4,30 Mld. USD. Zisk na akcii rostl o 16,2 % ročně za posledních 19 let. U IDEXX Laboratories je čistá marže 24,6 % nahoru oproti 23,2 % před několika lety. Konsenzuální 12měsíční cílová cena pro IDEXX Laboratories je 665,00 USD, asi pod cenu o 1,0 %. Z 21 analytiků jich 14 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie IDEXX Laboratories
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model IDEXX Laboratories a analýza akcií
Nejčastější otázky týkající se akcie IDEXX Laboratories
IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.
IDEXX Laboratories Inc is primarily active in the animal health industry.
The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.
IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.
IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.
IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.
IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.
Analytici aktuálně stanovují průměrnou cílovou cenu 665,00 USD pro akcii IDEXX Laboratories (medián: 665,00 USD), tedy -1,0 % vůči poslední ceně. Konsensus vychází z 21 hodnocení analytiků.
21 analytiků aktuálně hodnotí akcii IDEXX Laboratories: 14 doporučuje koupit, 7 držet a 0 prodat. Pro rok 2026 analytici očekávají u IDEXX Laboratories tržby 4,72 Mld. USD a zisk na akcii 14,84 USD.
Při aktuálním kurzu se akcie IDEXX Laboratories obchoduje za 600,42 EUR (672,04 USD).
Akcie IDEXX Laboratories (IDXX) je kótována na 9 burzách, mimo jiné: NASDAQ (IDXX), London (0J8P.L), SIX (Zürich) (IX1.SW), XETRA (IX1.DE), Frankfurt (IX1.F), München (IX1.MU), Düsseldorf (IX1.DU), Wien (IDXX.VI).
IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.
Tržby očekávané za IDEXX Laboratories činí 4,72 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za IDEXX Laboratories činí 1,20 Mld. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) IDEXX Laboratories je aktuálně 45,30. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie IDEXX Laboratories.
Poměr ceny k tržbám (P/S) IDEXX Laboratories je aktuálně 11,48. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie IDEXX Laboratories.
Score kvality pro IDEXX Laboratories je 9/10.
ISIN IDEXX Laboratories je US45168D1046. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN IDEXX Laboratories je 888210. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker IDEXX Laboratories je IDXX. Symbol tickeru se používá k obchodování akcií IDEXX Laboratories na burze.
IDEXX Laboratories akcie
IDEXX Laboratories Peer Group
IDEXX Laboratories Ticker
IDEXX Laboratories FIGI
Všechny fundamentální údaje o IDEXX Laboratories v podrobné analýze
Naše analýzy akcií společnosti IDEXX Laboratories zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti IDEXX Laboratories. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: